Tokyo, June 1, 2006 (JCN) - Medical & Biological Laboratories (MBL) announced on May 30 that it entered into a sales agreement with Immunodiagnostic Systems (IDS) of the UK as of March 31. Under the agreement, MBL receives exclusive rights to market 23 types of in vitro diagnostics products offered by IDS in Japan, including reagents for proteins and bone metabolism markers and an osteoporosis diagnostic product. As an initial step, MBL will begin marketing reagents for research on July 1.
